Innoviva Inc
Innoviva Inc (INVA) Covered Calls
As of September 25, 2026, INVA has 4 covered call opportunities in the coming three months. Return ranges from 12.4 to 48.5% until expiration. Annualized return ranges from 31.7 to 205.7%. The nearest expiration is November 20, 2026. Maximum potential profit is $981.
Read more
Running INVA covered calls helps you generate consistent income from Innoviva Inc's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Innoviva Inc involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best INVA covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if INVA stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling INVA covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Innoviva Inc covered call is worth writing.
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP.
The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Income-focused investors, long-term INVA holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling INVA covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Innoviva Inc covered calls come to you, already filtered for the metrics that matter.
Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV percentile73.81% Elevated
- Market cap (M$)1,534
- 52 weeks high-15.55%
- 52 weeks low28.51%
- Analyst recommendationBuy
1.80 - Target price$35.00
64.86% above the current stock price - Dividend—
- Payout ratio0.00%
- Earnings date2026-11-04
- P/E5.17
- Future P/E9.39
- EPS (ttm)4.10
- EPS growth next 5 years-15.80%
As of September 25, 2026
| 2026-12-18 | 86 | 30.00 | 48.22 | 0.05 | 1.20 | 981.00 | 48.47 | 205.71 | -0.25 | +0.18 | 4 | 1.15 |
| 2026-12-18 | 86 | 25.00 | 23.52 | 0.10 | 0.30 | 486.00 | 24.01 | 101.91 | -0.49 | +0.13 | 264 | 0.20 |
| 2026-11-20 | 58 | 22.50 | 11.17 | 0.25 | 0.55 | 251.00 | 12.40 | 78.04 | -1.24 | +0.26 | 100 | 0.30 |
| 2027-03-19 | 177 | 22.50 | 11.17 | 0.85 | 2.55 | 311.00 | 15.37 | 31.69 | -4.20 | +0.44 | 2 | 1.70 |
As of September 25, 2026
Sell covered calls with the data behind you
Find the best INVA covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.
Start your 14-day free trial→